IN2014CN02671A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02671A IN2014CN02671A IN2671CHN2014A IN2014CN02671A IN 2014CN02671 A IN2014CN02671 A IN 2014CN02671A IN 2671CHN2014 A IN2671CHN2014 A IN 2671CHN2014A IN 2014CN02671 A IN2014CN02671 A IN 2014CN02671A
- Authority
- IN
- India
- Prior art keywords
- formula
- compound
- administering
- treating
- combination
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 201000003914 endometrial carcinoma Diseases 0.000 abstract 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003881 letrozole Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161534836P | 2011-09-14 | 2011-09-14 | |
| US201161543529P | 2011-10-05 | 2011-10-05 | |
| US201161562670P | 2011-11-22 | 2011-11-22 | |
| PCT/US2012/055387 WO2013040337A1 (en) | 2011-09-14 | 2012-09-14 | Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02671A true IN2014CN02671A (enExample) | 2015-07-03 |
Family
ID=46940622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2671CHN2014 IN2014CN02671A (enExample) | 2011-09-14 | 2012-09-14 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2755654A1 (enExample) |
| KR (1) | KR20140077911A (enExample) |
| AU (1) | AU2012308414A1 (enExample) |
| BR (1) | BR112014005858A2 (enExample) |
| CA (1) | CA2848724A1 (enExample) |
| IL (1) | IL231448A0 (enExample) |
| IN (1) | IN2014CN02671A (enExample) |
| TW (1) | TW201325592A (enExample) |
| UY (1) | UY34339A (enExample) |
| WO (1) | WO2013040337A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113754565B (zh) * | 2021-11-09 | 2022-02-22 | 南京威凯尔生物医药科技有限公司 | 一种连续流微反应器中制备沙库巴曲中间体的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US7019002B2 (en) | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
| WO2007044729A2 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| EP1940839B1 (en) | 2005-10-07 | 2013-07-31 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha |
| WO2007044481A1 (en) | 2005-10-07 | 2007-04-19 | Basf Corporation | Clearcoat coating composition |
| RS53020B (sr) * | 2007-04-11 | 2014-04-30 | Exelixis Inc. | Kombinovane terapije koje sadrže hinoksalin inhibitor pi3k-alfa za upotrebu u lečenju kancera |
| WO2010146391A1 (en) * | 2009-06-15 | 2010-12-23 | Generics [Uk] Limited | Regioselective synthesis of letrozole |
| WO2012065057A2 (en) * | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
-
2012
- 2012-09-14 IN IN2671CHN2014 patent/IN2014CN02671A/en unknown
- 2012-09-14 TW TW101133789A patent/TW201325592A/zh unknown
- 2012-09-14 BR BR112014005858A patent/BR112014005858A2/pt not_active Application Discontinuation
- 2012-09-14 KR KR1020147009539A patent/KR20140077911A/ko not_active Withdrawn
- 2012-09-14 AU AU2012308414A patent/AU2012308414A1/en not_active Abandoned
- 2012-09-14 CA CA2848724A patent/CA2848724A1/en not_active Abandoned
- 2012-09-14 UY UY0001034339A patent/UY34339A/es not_active Application Discontinuation
- 2012-09-14 EP EP12766542.0A patent/EP2755654A1/en not_active Withdrawn
- 2012-09-14 WO PCT/US2012/055387 patent/WO2013040337A1/en not_active Ceased
-
2014
- 2014-03-11 IL IL231448A patent/IL231448A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013040337A1 (en) | 2013-03-21 |
| TW201325592A (zh) | 2013-07-01 |
| IL231448A0 (en) | 2014-04-30 |
| WO2013040337A9 (en) | 2014-04-03 |
| UY34339A (es) | 2013-04-30 |
| CA2848724A1 (en) | 2013-03-21 |
| BR112014005858A2 (pt) | 2017-06-13 |
| EP2755654A1 (en) | 2014-07-23 |
| KR20140077911A (ko) | 2014-06-24 |
| AU2012308414A1 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501058A1 (en) | Pyrimidine-2,4-diamine derivatives for treatment of cancer | |
| PH12012501719A1 (en) | Compounds for immunoproteasome inhibition | |
| MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
| CA2909625C (en) | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer | |
| MX2013011329A (es) | Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso. | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| MX2013012695A (es) | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. | |
| MX2014005458A (es) | Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer. | |
| PH12014502047A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| GEP201706612B (en) | Methods for the treatment of breast cancer | |
| NZ700612A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| PH12014502046A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| GEP201706690B (en) | Novel process for making compounds for use in treatment of cancer | |
| PH12015501038A1 (en) | Inhibitors of iap | |
| MX351863B (es) | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. | |
| PH12015500867B1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| TN2012000469A1 (en) | Use of novel pan-cdk inhibitors for treating tumors | |
| MX2013012486A (es) | Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor). | |
| IN2014CN02671A (enExample) | ||
| PH12014500973A1 (en) | Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies | |
| EA201491506A1 (ru) | Новое применение кабазитаксела в педиатрии | |
| NZ709094A (en) | Pyrimidine-2,4-diamine derivatives for treatment of cancer | |
| TN2011000013A1 (en) | Amidophenoxyindazoles useful as inhibitors of c-met |